HER-2/neu在人膀胱癌组织的表达及其siRNA对膀胱癌细胞生物学行为的影响
|
摘要
膀胱肿瘤是泌尿外科最常见的肿瘤,在全世界范围内膀胱肿瘤的发病率在男性占全身肿瘤的第8位,标准发病率在男性为9.9/10万,在女性为第25位,标准发病率2.3/10万。在我国膀胱肿瘤也是泌尿外科最常见的肿瘤,膀胱移行细胞癌(Bladder Transitional CellCarcinoma,BTCC)是最常见的膀胱恶性肿瘤,占其中的92.8%。膀胱肿瘤的产生、浸润、转移和复发是一个多阶段复杂的过程,与许多癌基因的激活有关。超过50%的癌基因、原癌基因产物都具有酪氨酸激酶(receptor tyrosine kinase,RTK)活性,RTK类癌基因,包括HER-1(EGFR)、HER-2/neu(human epidermal growth factorreceptor-2)、HER-3、HER-4等,HER-2/neu起核心作用。HER-2/neu的活化信号可以转导下游分子,介导多种生化反应,产生广泛的生物学效应,在细胞的增殖、分化、抗凋亡等过程中起重要作用。HER-2/neu过表达与多种肿瘤的发生发展、化疗耐受、放疗抵抗等相关。HER-2/neu基因在膀胱肿瘤的发生、发展中扮演何种角色仍不十分清楚。国内外现在仍未见HER-2/neu的小干扰RNA(small interfering RNA,siRNA)转染BTCC细胞系的实验研究报道。我们的实验首次使用siRNA抑制膀胱癌细胞株T24中HER-2/neu基因的表达,研究HER-2/neu在膀胱癌发生、发展中的作用,探讨膀胱癌基因治疗的新途径。
第一章人膀胱移行细胞癌组织中HER-2/neu表达的研究
目的:从mRNA和蛋白水平研究癌基因HER-2/neu在BTCC及正常膀胱粘膜组织中的表达,结合临床病理特征研究HER-2/neu在BTCC发生发展中的作用。
方法:采用RT-PCR和免疫组化从mRNA和蛋白水平检测BTCC及正常膀胱粘膜组织中HER-2/neu的表达,分析HER-2/neu表达与肿瘤发生、肿瘤临床分期、病理分级的关系。
结果:BTCC中HER-2/neu mRNA表达率为57.1%,较正常膀胱粘膜组织(表达率5.0%)明显升高。随着临床分期、病理分期的升高,HER-2/neu mRNA在BTCC表达量增多。BTCC中HER-2/neu蛋白阳性率为43.1%,较正常膀胱粘膜组织(阳性率5.0%)明显升高。HER-2/neu蛋白在中低分化(Ⅱ、Ⅲ)BTCC中的阳性率明显高于高分化(Ⅰ)BTCC。HER-2/neu蛋白在浸润性(T2-T4)BTCC中的阳性率明显高于表浅性(Tis-T1)BTCC。随着病理分期的升高,HER-2/neu蛋白在BTCC阳性率增多。HER-2/neu蛋白、PCNA蛋白在BTCC中表达为正相关性,相关系数为0.336。以上差异均有显著性(P＜0.05)。BTCC中HER-2/neu mRNA、HER-2/neu蛋白表达与性别、年龄、初复发、单多发、复发前是否灌注治疗等因素无关。
结论:HER-2/neu mRNA、HER-2/neu蛋白均在BTCC中表达异常增强,在BTCC发生、发展过程中起重要作用。HER-2/neu可作为诊断、判断预后、指导治疗、随访检测的指标。HER-2/neu基因可能成为BTCC新的治疗靶点。
第二章针对HER-2/neu基因的siRNA表达载体的构建及鉴定
目的:为研究针对HER-2/neu基因的siRNA对BTCC细胞系体外生物学行为的影响,构建插入siRNA的重组质粒pGenesil-1。
方法:HER-2/neu mRNA完整序列为模板,网上在线设计两条针对CDS区的siRNA序列,BLAST同源分析证实其特异性,同时设阴性对照shHK和阳性对照shGAPDH。寡核苷酸链合成,退火磷酸化后生成双链DNA,与线性化的质粒pGenesil-1连接。转化感受态的大肠杆菌,鉴定阳性克隆,质粒酶切、测序鉴定。
结果:质粒酶切鉴定可见约400bp的DNA小带,与预期相符。测序也证明重组质粒序列与设计序列完全一致。证明针对HER-2/neu基因的siRNA表达载体已构建成功。
结论:成功构建了包含针对HER-2/neu基因的siRNA的重组质粒pGenesil-1,这为后期的稳定转染、抗性筛选挑取单克隆细胞株奠定了试验基础。
第三章RNA干扰抑制膀胱癌细胞株T24 HER-2/neu的表达
目的:为研究针对HER-2/neu基因的siRNA对BTCC细胞系体外生物学特性的影响,建立了稳定表达siRNA的BTCC细胞株T24,并探讨siRNA对HER-2/neu mRNA、HER-2/neu蛋白表达的影响。
方法:将质粒P0(空质粒),质粒P1(包含shHER-2/neu-1)、质粒P2(包含shHER-2/neu-2)、质粒P3(包含shHK)、质粒P4(包含shGAPDH)瞬时转染T24细胞,分别命名为T24-P0、T24-P1、T24-P2、T24-P3、T24-P4细胞。荧光显微镜观察转染效率,RT-PCR筛选出RNA干扰效果最好的重组质粒。G418筛选阳性克隆,建立稳转细胞系,RT-PCR、Western Blot检测HER-2/neu基因沉默效果。
结果:T24-P1、T24-P2克隆较T24-P0克隆小,克隆生长较为缓慢,细胞的形态无明显差别。RT-PCR发现T24、空载体转染的T24-P0、阴性对照T24-P3三者目的条带亮度相当。而T24-P1、T24-P2的目的条带较前三者弱,T24-P2尤为明显。与T24相比,T24-P2细胞HER-2/neu mRNA的表达量被抑制了54.45%。T24-P2 HER-2/neu蛋白的表达比T24、T24-P0明显下降。T24 HER-2/neu蛋白表达量约为T24-P2的2.12倍,而T24、T24-P0 HER-2/neu蛋白表达量无明显差异。
结论:成功构建了稳定表达针对HER-2/neu基因的siRNA的BTCC细胞株,质粒P1、P2转染对细胞HER-2/neu mRNA和蛋白的表达量均有抑制,为下一步HER-2/neu的功能研究提供了实验基础。
第四章RNA干扰HER-2/neu表达对膀胱癌细胞生物学行为的影响
目的:研究HER-2/neu siRNA对BTCC细胞系T24体外增殖、凋亡、迁移侵袭能力的影响及其可能机理。
方法:以成功构建的稳定表达siRNA的T24-P2、T24-P0为研究对象,以未转染的T24为对照,绘制三组细胞的生长曲线比较生长差异,计算细胞倍增时间;MTT法比较三组细胞存活率的差异;流式细胞仪检测三组细胞周期和凋亡的改变;集落形成试验检验三组细胞增殖能力的差异;细胞粘附实验、划痕实验、Transwell小室检测三组细胞体外侵袭力的变化。
结果:T24、T24-P0的各项指标无明显差异。与前两组相比,T24-P2生长明显缓慢,从第三天开始生长速度明显低于前两组,至对数生长期更明显,生长曲线较平缓;T24-P2细胞倍增时间30.06小时左右,延长约5小时。T24-P2存活率明显下降,最低时细胞生长被抑制了将近一半。T24-P2处于细胞前期(G0/G1期)的比例明显增加(80.13%),细胞中期(S期)的比例明显减少,凋亡细胞比例明显增多(31.08%),在G1期前出现明显的凋亡峰。T24-P2克隆速度明显减慢,细胞形态皱缩、边缘不整,出现凋亡小体,集落形成率明显低于前两组(31.70%),而集落抑制率明显高于前两组(56.93%)。T24-P2细胞粘附力明显下降。T24-P2迁移到划痕区的细胞数明显低于前两组,说明侵袭力下降。T24-P2穿过Matrigel滤膜的细胞数明显低于前两组,说明侵袭力受抑制。以上差异均具有显著性(P＜0.05)。
结论:HER-2/neu干扰质粒P2稳定转染可抑制BTCC细胞株T24的体外生长,使细胞倍增时间延长,细胞周期停滞在G1/G2期,促进癌细胞凋亡,抑制癌细胞的体外粘附、迁移侵袭能力。这种抑制作用可能与siRNA下调HER-2/neu表达有关。
Bladder cancer was the most common cancer in urology. The incidence of bladder cancer in the male was the eighth in all tumor in the world, and standards incidence of male was 9.9/10 million; while twenty fifth in female, 2.3/10 million. Bladder cancer was still the most common cancer in urology in our country. BTCC (bladder transitional cell carcinoma) was the most common malignant tumor of the bladder, account for 92.8%. The produce、invasion、metastasis and recurrence of BTCC were a multi-stage、complex process, having relationship with many oncogene activation. More than 50% of the oncogene、oncogene product had tyrosine kinase activity. HER-2/neu played a central role in the oncogenes type of RTK including HER-1 (EGFR)、HER-2/neu、HER-3、HER-4. Signals activated by HER-2/neu could transduct to downstream molecules, mediate variety of biochemical reactions, produce a wide range of biological effects, and play an important role in cell proliferation、differentiation、anti-apoptosis. Over-expression of HER-2/neu had relationship with development、chemotherapy resistance、radiation resistance of a variety tumors. What kind of role HER-2/neu playing was not yet very clear in development of BTCC. Experimental study on siRNA of HER-2/neu transfecting BTCC cell lines was not yet reported at home and abroad. The first time in the world we used siRNA to inhibit BTCC cell line T24 to reduce the HER-2/neu gene expression, to study function of HER-2/neu in BTCC generation and development, then to explore a new way of gene therapy in BTCC.
Chapter I The expression of HER-2/neu mRNA and protein in bladder transitional cell carcinoma
Objective: To study the expression of HER-2/neu mRNA、HER-2/neu protein in BTCC and the normal bladder mucosa, evaluate the possible role in BTCC development by the clinical、pathological features.
Methods: HER-2/neu mRNA and HER-2/neu protein were examined by RT-PCR and immunohistochemistry respectively in BTCC and the normal bladder mucosa. The correlations between the expression of HER-2/neu and tumor grade、stage were closely studied.
Results: The expression of HER-2/neu mRNA in BTCC was 57.1%, higher than the normal bladder mucosa. Along with clinical stage、pathological stage increasing, the expression of HER-2/neu mRNA was more and more. The expression of HER-2/neu protein in BTCC was 43.1 %, higher than the normal bladder mucosa. The expression of HER-2/neu protein in II、III BTCC was higher than the I BTCC. The expression of HER-2/neu protein in T2-T4 BTCC was higher than Tis-T1 BTCC. Along with pathological stage increasing, the expression of HER-2/neu protein was more and more. There was the positive correlation between HER-2/neu protein、PCNA protein in BTCC, and the correlation coefficient was 0.336. HER-2/neu mRNA、HER-2/neu protein had no relationship with gender、age、recurrence、multiple and reperfusion therapy.
Conclusion: The abnormal expression of HER-2/neu was common in BTCC, which playing an important role in the development of BTCC. HER-2/neu would be a useful predictor of diagnosis、prognosis、treatments follow-up testing. HER-2/neu gene would be a new therapeutic target.
Chapter II Construction and identification vector expressing siRNA on HER-2/neu
Objective: To study the effect of siRNA on HER-2/neu gene expression and biological behavior of BTCC cell line, we established and identified the recombinant plasmid pGenesil-1.
Method: Complete sequence of HER-2/neu gene as a template, designed two siRNA sequences for the CDS online, BLAST confirming its specificity. Negative control shHK and positive control shGAPDH were used at the same time. Annealing、phosphorylating oligonucleotide chain, dsDNA connected linearized plasmid pGenesil-1. Plasmid transformated state feelings E. coli. The constructed vectors expressing siRNA were digested with enzymes, and positive clones having been inserted sequences were confirmed by DNA sequencing.
Result: DNA sequencing results of positive clones were the same with our designation.
Conclusion: Recombinant plasmid pGenesil-1 including siRNA on HER-2/neu gene was constructed successfully.
ChapterIII Surpression of HER-2/neu gene expression by using siRNA in T24 cell line
Objective: To explore the effect of siRNA on HER-2/neu on the BTCC cell in vitro, T24 that stable expressing siRNA was constructed. HER-2/neu mRNA and protein expression of T24 were detected by RT-PCR、Western Blot.
Method: Five plasmids: P0(Empty plasmid)、P1(shHER-2/neu-1)、P2(shHER-2/neu-2)、P3(shHK)、P4(shGAPDH) were transferred respectively into T24 in vitro by using lipfectamine. Transfection efficiency was detected by fluorescence microscopy. Cells were selected by G418 and the positive cell clones were chosen、expanded culture. The expression of HER-2/neu gene on the levels of mRNA and protein were determined respectively by RT-PCR、western blot.
Result: The clones of T24-P1、T24-P2 were smaller than T24, and grew slowly. HER-2/neu mRNA of T24、T24-P0、T24-P3 were same by RT-PCR, but HER-2/neu mRNA of T24-P1、T24-P2 were less, T24-P2 specially. HER-2/neu mRNA of T24-P2 was inhibited about 54.45%. HER-2/neu protein of T24-P2 was less than T24、T24-P0, but HER-2/neu protein of the latter two were same.
Conclusion: We successfully established BTCC cells that could stably express the siRNA on HER-2/neu gene and empty plasmid pGenesil-1 respectively. The expression of HER-2/neu mRNA and protein were inhibited by P1、P2. It provided a foundation for post experimentation.
Objective: To investigate whether the RNA interference on HER-2/neu could inhibited the growth、apotosis、motility、invasion of BTCC cell lines in vitro and to explore the possible mechanism.
Methods: BTCC cell lines T24-P2、T24-P0 and T24 were taken as our object. Cell growth curve was obtained by cell counter and cell doubling time was computed. Cell survival rate was measured by MTT assay. Flow cytometry was used to analyze the cell cycle and cell apoptosis. Cell proliferation was measured by colony-forming test. The motility and invasion ability in vitro were obtained by cell adhere assay、scratch assay and matrigel invasion assay.
Results: T24 and T24-P0 had no obvious different in all indicators, morphology shrinkaged、edge incomplete、apoptotic bodies appearing in T24. Compared with the other two groups, T24-P2 grew more slowly, having lower survival rate、higher proportion of cells in G0/G1 phase and higher in the apoptosis、lower in colony formation rate、motility and invasion ability.
Conclusions: Transferring P2 could inhibit the growth、motility、invasion of BTCC cell T24 in vitro. This effect was possibly atributed to suppressing HER-2/neu mRNA and protein.
第一章人膀胱移行细胞癌组织中HER-2/neu表达的研究
目的:从mRNA和蛋白水平研究癌基因HER-2/neu在BTCC及正常膀胱粘膜组织中的表达,结合临床病理特征研究HER-2/neu在BTCC发生发展中的作用。
方法:采用RT-PCR和免疫组化从mRNA和蛋白水平检测BTCC及正常膀胱粘膜组织中HER-2/neu的表达,分析HER-2/neu表达与肿瘤发生、肿瘤临床分期、病理分级的关系。
结果:BTCC中HER-2/neu mRNA表达率为57.1%,较正常膀胱粘膜组织(表达率5.0%)明显升高。随着临床分期、病理分期的升高,HER-2/neu mRNA在BTCC表达量增多。BTCC中HER-2/neu蛋白阳性率为43.1%,较正常膀胱粘膜组织(阳性率5.0%)明显升高。HER-2/neu蛋白在中低分化(Ⅱ、Ⅲ)BTCC中的阳性率明显高于高分化(Ⅰ)BTCC。HER-2/neu蛋白在浸润性(T2-T4)BTCC中的阳性率明显高于表浅性(Tis-T1)BTCC。随着病理分期的升高,HER-2/neu蛋白在BTCC阳性率增多。HER-2/neu蛋白、PCNA蛋白在BTCC中表达为正相关性,相关系数为0.336。以上差异均有显著性(P＜0.05)。BTCC中HER-2/neu mRNA、HER-2/neu蛋白表达与性别、年龄、初复发、单多发、复发前是否灌注治疗等因素无关。
结论:HER-2/neu mRNA、HER-2/neu蛋白均在BTCC中表达异常增强,在BTCC发生、发展过程中起重要作用。HER-2/neu可作为诊断、判断预后、指导治疗、随访检测的指标。HER-2/neu基因可能成为BTCC新的治疗靶点。
第二章针对HER-2/neu基因的siRNA表达载体的构建及鉴定
目的:为研究针对HER-2/neu基因的siRNA对BTCC细胞系体外生物学行为的影响,构建插入siRNA的重组质粒pGenesil-1。
方法:HER-2/neu mRNA完整序列为模板,网上在线设计两条针对CDS区的siRNA序列,BLAST同源分析证实其特异性,同时设阴性对照shHK和阳性对照shGAPDH。寡核苷酸链合成,退火磷酸化后生成双链DNA,与线性化的质粒pGenesil-1连接。转化感受态的大肠杆菌,鉴定阳性克隆,质粒酶切、测序鉴定。
结果:质粒酶切鉴定可见约400bp的DNA小带,与预期相符。测序也证明重组质粒序列与设计序列完全一致。证明针对HER-2/neu基因的siRNA表达载体已构建成功。
结论:成功构建了包含针对HER-2/neu基因的siRNA的重组质粒pGenesil-1,这为后期的稳定转染、抗性筛选挑取单克隆细胞株奠定了试验基础。
第三章RNA干扰抑制膀胱癌细胞株T24 HER-2/neu的表达
目的:为研究针对HER-2/neu基因的siRNA对BTCC细胞系体外生物学特性的影响,建立了稳定表达siRNA的BTCC细胞株T24,并探讨siRNA对HER-2/neu mRNA、HER-2/neu蛋白表达的影响。
方法:将质粒P0(空质粒),质粒P1(包含shHER-2/neu-1)、质粒P2(包含shHER-2/neu-2)、质粒P3(包含shHK)、质粒P4(包含shGAPDH)瞬时转染T24细胞,分别命名为T24-P0、T24-P1、T24-P2、T24-P3、T24-P4细胞。荧光显微镜观察转染效率,RT-PCR筛选出RNA干扰效果最好的重组质粒。G418筛选阳性克隆,建立稳转细胞系,RT-PCR、Western Blot检测HER-2/neu基因沉默效果。
结果:T24-P1、T24-P2克隆较T24-P0克隆小,克隆生长较为缓慢,细胞的形态无明显差别。RT-PCR发现T24、空载体转染的T24-P0、阴性对照T24-P3三者目的条带亮度相当。而T24-P1、T24-P2的目的条带较前三者弱,T24-P2尤为明显。与T24相比,T24-P2细胞HER-2/neu mRNA的表达量被抑制了54.45%。T24-P2 HER-2/neu蛋白的表达比T24、T24-P0明显下降。T24 HER-2/neu蛋白表达量约为T24-P2的2.12倍,而T24、T24-P0 HER-2/neu蛋白表达量无明显差异。
结论:成功构建了稳定表达针对HER-2/neu基因的siRNA的BTCC细胞株,质粒P1、P2转染对细胞HER-2/neu mRNA和蛋白的表达量均有抑制,为下一步HER-2/neu的功能研究提供了实验基础。
第四章RNA干扰HER-2/neu表达对膀胱癌细胞生物学行为的影响
目的:研究HER-2/neu siRNA对BTCC细胞系T24体外增殖、凋亡、迁移侵袭能力的影响及其可能机理。
方法:以成功构建的稳定表达siRNA的T24-P2、T24-P0为研究对象,以未转染的T24为对照,绘制三组细胞的生长曲线比较生长差异,计算细胞倍增时间;MTT法比较三组细胞存活率的差异;流式细胞仪检测三组细胞周期和凋亡的改变;集落形成试验检验三组细胞增殖能力的差异;细胞粘附实验、划痕实验、Transwell小室检测三组细胞体外侵袭力的变化。
结果:T24、T24-P0的各项指标无明显差异。与前两组相比,T24-P2生长明显缓慢,从第三天开始生长速度明显低于前两组,至对数生长期更明显,生长曲线较平缓;T24-P2细胞倍增时间30.06小时左右,延长约5小时。T24-P2存活率明显下降,最低时细胞生长被抑制了将近一半。T24-P2处于细胞前期(G0/G1期)的比例明显增加(80.13%),细胞中期(S期)的比例明显减少,凋亡细胞比例明显增多(31.08%),在G1期前出现明显的凋亡峰。T24-P2克隆速度明显减慢,细胞形态皱缩、边缘不整,出现凋亡小体,集落形成率明显低于前两组(31.70%),而集落抑制率明显高于前两组(56.93%)。T24-P2细胞粘附力明显下降。T24-P2迁移到划痕区的细胞数明显低于前两组,说明侵袭力下降。T24-P2穿过Matrigel滤膜的细胞数明显低于前两组,说明侵袭力受抑制。以上差异均具有显著性(P＜0.05)。
结论:HER-2/neu干扰质粒P2稳定转染可抑制BTCC细胞株T24的体外生长,使细胞倍增时间延长,细胞周期停滞在G1/G2期,促进癌细胞凋亡,抑制癌细胞的体外粘附、迁移侵袭能力。这种抑制作用可能与siRNA下调HER-2/neu表达有关。
Bladder cancer was the most common cancer in urology. The incidence of bladder cancer in the male was the eighth in all tumor in the world, and standards incidence of male was 9.9/10 million; while twenty fifth in female, 2.3/10 million. Bladder cancer was still the most common cancer in urology in our country. BTCC (bladder transitional cell carcinoma) was the most common malignant tumor of the bladder, account for 92.8%. The produce、invasion、metastasis and recurrence of BTCC were a multi-stage、complex process, having relationship with many oncogene activation. More than 50% of the oncogene、oncogene product had tyrosine kinase activity. HER-2/neu played a central role in the oncogenes type of RTK including HER-1 (EGFR)、HER-2/neu、HER-3、HER-4. Signals activated by HER-2/neu could transduct to downstream molecules, mediate variety of biochemical reactions, produce a wide range of biological effects, and play an important role in cell proliferation、differentiation、anti-apoptosis. Over-expression of HER-2/neu had relationship with development、chemotherapy resistance、radiation resistance of a variety tumors. What kind of role HER-2/neu playing was not yet very clear in development of BTCC. Experimental study on siRNA of HER-2/neu transfecting BTCC cell lines was not yet reported at home and abroad. The first time in the world we used siRNA to inhibit BTCC cell line T24 to reduce the HER-2/neu gene expression, to study function of HER-2/neu in BTCC generation and development, then to explore a new way of gene therapy in BTCC.
Chapter I The expression of HER-2/neu mRNA and protein in bladder transitional cell carcinoma
Objective: To study the expression of HER-2/neu mRNA、HER-2/neu protein in BTCC and the normal bladder mucosa, evaluate the possible role in BTCC development by the clinical、pathological features.
Methods: HER-2/neu mRNA and HER-2/neu protein were examined by RT-PCR and immunohistochemistry respectively in BTCC and the normal bladder mucosa. The correlations between the expression of HER-2/neu and tumor grade、stage were closely studied.
Results: The expression of HER-2/neu mRNA in BTCC was 57.1%, higher than the normal bladder mucosa. Along with clinical stage、pathological stage increasing, the expression of HER-2/neu mRNA was more and more. The expression of HER-2/neu protein in BTCC was 43.1 %, higher than the normal bladder mucosa. The expression of HER-2/neu protein in II、III BTCC was higher than the I BTCC. The expression of HER-2/neu protein in T2-T4 BTCC was higher than Tis-T1 BTCC. Along with pathological stage increasing, the expression of HER-2/neu protein was more and more. There was the positive correlation between HER-2/neu protein、PCNA protein in BTCC, and the correlation coefficient was 0.336. HER-2/neu mRNA、HER-2/neu protein had no relationship with gender、age、recurrence、multiple and reperfusion therapy.
Conclusion: The abnormal expression of HER-2/neu was common in BTCC, which playing an important role in the development of BTCC. HER-2/neu would be a useful predictor of diagnosis、prognosis、treatments follow-up testing. HER-2/neu gene would be a new therapeutic target.
Chapter II Construction and identification vector expressing siRNA on HER-2/neu
Objective: To study the effect of siRNA on HER-2/neu gene expression and biological behavior of BTCC cell line, we established and identified the recombinant plasmid pGenesil-1.
Method: Complete sequence of HER-2/neu gene as a template, designed two siRNA sequences for the CDS online, BLAST confirming its specificity. Negative control shHK and positive control shGAPDH were used at the same time. Annealing、phosphorylating oligonucleotide chain, dsDNA connected linearized plasmid pGenesil-1. Plasmid transformated state feelings E. coli. The constructed vectors expressing siRNA were digested with enzymes, and positive clones having been inserted sequences were confirmed by DNA sequencing.
Result: DNA sequencing results of positive clones were the same with our designation.
Conclusion: Recombinant plasmid pGenesil-1 including siRNA on HER-2/neu gene was constructed successfully.
ChapterIII Surpression of HER-2/neu gene expression by using siRNA in T24 cell line
Objective: To explore the effect of siRNA on HER-2/neu on the BTCC cell in vitro, T24 that stable expressing siRNA was constructed. HER-2/neu mRNA and protein expression of T24 were detected by RT-PCR、Western Blot.
Method: Five plasmids: P0(Empty plasmid)、P1(shHER-2/neu-1)、P2(shHER-2/neu-2)、P3(shHK)、P4(shGAPDH) were transferred respectively into T24 in vitro by using lipfectamine. Transfection efficiency was detected by fluorescence microscopy. Cells were selected by G418 and the positive cell clones were chosen、expanded culture. The expression of HER-2/neu gene on the levels of mRNA and protein were determined respectively by RT-PCR、western blot.
Result: The clones of T24-P1、T24-P2 were smaller than T24, and grew slowly. HER-2/neu mRNA of T24、T24-P0、T24-P3 were same by RT-PCR, but HER-2/neu mRNA of T24-P1、T24-P2 were less, T24-P2 specially. HER-2/neu mRNA of T24-P2 was inhibited about 54.45%. HER-2/neu protein of T24-P2 was less than T24、T24-P0, but HER-2/neu protein of the latter two were same.
Conclusion: We successfully established BTCC cells that could stably express the siRNA on HER-2/neu gene and empty plasmid pGenesil-1 respectively. The expression of HER-2/neu mRNA and protein were inhibited by P1、P2. It provided a foundation for post experimentation.
Objective: To investigate whether the RNA interference on HER-2/neu could inhibited the growth、apotosis、motility、invasion of BTCC cell lines in vitro and to explore the possible mechanism.
Methods: BTCC cell lines T24-P2、T24-P0 and T24 were taken as our object. Cell growth curve was obtained by cell counter and cell doubling time was computed. Cell survival rate was measured by MTT assay. Flow cytometry was used to analyze the cell cycle and cell apoptosis. Cell proliferation was measured by colony-forming test. The motility and invasion ability in vitro were obtained by cell adhere assay、scratch assay and matrigel invasion assay.
Results: T24 and T24-P0 had no obvious different in all indicators, morphology shrinkaged、edge incomplete、apoptotic bodies appearing in T24. Compared with the other two groups, T24-P2 grew more slowly, having lower survival rate、higher proportion of cells in G0/G1 phase and higher in the apoptosis、lower in colony formation rate、motility and invasion ability.
Conclusions: Transferring P2 could inhibit the growth、motility、invasion of BTCC cell T24 in vitro. This effect was possibly atributed to suppressing HER-2/neu mRNA and protein.
引文
[1]吴阶平。吴阶平泌尿外科学。济南:山东科学技术出版社,2004。921。
[2]Kwak C,Ku JH,Park JY,et al.Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T_1 Grade 3 bladder cancer.Joural of Urology,2004(1):149-152.
[3]苏定冯,缪朝玉,王永铭。2003药理学进展。北京:人民卫生出版社,2003。46。
[4]Yoshikawa D,Ojima H,Iwasaki M,et al.Clinicopathological and prognostic significance of EGFR,VEGF,and HER2 expression in cholangiocarcinoma,2008,98(2):418-425.
[5]Barnes DM,Meyer JS,Gonzalez JG,et al.Relationship between cerb-B2immunoreactivity and thymidine labeling index in breast carcinoma in situ.Breast Cancer Res Treat,1991,18(1):11-17.
[6]Zhong W,Peng J,He H,et al.Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia,2008,31(1):ES-E15.
[7]Pinkas-Kramarski R,Soussan L,Waterman H,et al.Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions,1996,15(10):2452-2467.
[8]Amsellem-Ouazana D,Bieche I,Molinie V,et al.Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol,2006,49(6):1035-1042.
[9]Hauser-Kronberger C,Peham K,Grall J,et al.Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder.J Urol,2006,175(3):875-880.
[10]Coogan CL,Estrada CR,Kapur S,et al..HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.Urology,2004,63(4):786-790.
[11]Wulfing C,von Struensee D,Bierer S,et al.Expression of Her2/neu in locally advanced bladder cancer:implication for a molecular targeted therapy.Aktuelle Urol,2005,36(5):423-429.
[12]Gardmark T,Wester K,De la Torre M,et al.Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.BJU Int,2005,95(7):982-986.
[13]Lake-Bakaar G,Mazzoccoli V,Ruffini L.Digital image analysis of the distribution of proliferating cell muclear antigen in hepatitis C virus relates chronic hepatitis,crirrhosis,and hepatocellular carcinoma.Dig Dis Sci,2002,47(7):1644-1648.
[14]Tsujihashi H,Nakanishi A,Matsuda H,et al.Cell proliferation of human bladder tumors determined by BRDURD and Ki-67immunostaining.J Urol,1991,145(4):846-849.
[15]Vogl G,Bartel H,Dietze O,etal.HER-2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.Appl Immunohistochem Mol Morphol,2006:14(2):138-145.
[16]Folkman J,Browder T,Palmblad J.Angiogenesis research:Guidelines for translation to clinical application.Thromb Haemost,2001,86(1):23-33.
[17]Wen XF,Yang G,Mao W,et al.HER-2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways:implications for HER-2-targeted antibody therapy.Oncogene,2006,25(52):6986-6996.
[18]Grothey A.Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.Semin Oncol,2006,33(5):41-49.
[19]Carter WB.HER-2 signaling-induced micro vessel dismantling.Surgery,2001,130(2):382-387.
[20]Tsai YS,Tzai TS,Chow NH.Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol hat,2007,79(3):210-216.
[21]Nakano T,Oka K,Ishikawa A.Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer.Cancer Detect Prev,1998,22(2):120-128.
[22]Colomer R,Llombart-Cussac A,Lloveras B,et al.High circulating HER2extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer:A confirmatory prospective study.Cancer,2007,110(10):2178-2185.
[23]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cell.Nature,2000,404(6775):293-296.
[24]Elbashir SM,Martinez J,Patkaniowska A,et al.Furetional anatomy of siRNAs for mediating eflicient RNAi in Drosophila melanogaster embryo Lysate.EMBO J,2001,20(23):6877-6888.
[25]Reynolds A,Leake D,Boese Q,et al.Rational siRNA design for RNA interference.,2004,22(3):326-330.
[26]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[27]Soutschek J,Akinc A,Bramlage B,et al.Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.Nature,2004,432(7014):173-178.
[28]Raica M,Zylis D,Cimpean AM.Cytokeratin 20,34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma.Rom J Morphol Embryol,2005,46(1):11-15.
[29]Masliukova EA,Pozharisskii KM,Karelin MI,et al.Role of Ki-67,mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer.Vopr Onkol,2006,52(6):643-648.
[30]Papazisis KT,Habeshaw T,Miles DW,et,al.Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer.A review of the existing clinical trials and results of the expanded access programme in the UK.Int J Clin Pract,2004.58(6):581-586.
[31]Graus-Porta D,Beerli RR,Hynes NE.Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.Mol Cell Biol,1995,15(3):1182-1191.
[32]邱学德,刘乔保,王田等。酪氨酸激酶抑制剂PD168393对HER2不同表达水平膀胱癌细胞株的作用研究。中华肿瘤防治杂志,2006,13(8):604-607。
[33]Nagasawa J,Mizokami A,Koshida K,et al.Novel HER2 selective tyrosine kinase inhibitor,TAK-165,inhibits bladder,kidney and androgen-independent prostate cancer in vitro and in vivo.hat J Urol,2006,13(5):587-592.
[34]Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3'overhangs efficiently suppress targeted gene expression in mammalian cells.Nat Biotechnol,2002,20(5):497-500.
[35]Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296(5567):550-553.
[36]Bernstein E,Caudy AA,Hammond SM,et al.Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature,2001,409(6818):363-366.
[37]Hannon GJ.RNA interference.Nature,2002,418(6894):244-251.
[38]Nykanen A,Haley B,Zamore PD.ATP requirements and small interfering RNA structuire in the RNA interference pathway.Cell,2001,107(3):309-321.
[39]Zamore PD.RNA interference:listening to the sound of silence.Nat Struct Biol,2001,8(9):746-750.
[40]Akiyama S,Furukawa T,Sumizawa T,et al.The role of thymidine phosphorylase,an angiogenic enzyme,in tumor progression.Cancer Sci,2004,95(11):851-857.
[41]Awwad RA,Sergina N,Yang H,et al.The role of transforming growth factor alpha in determining growth factor independence.Cancer Res,2003,63(15):4731-4738.
[42]Chung LW,Baseman A,Ass ikis V,et al.Molecular insights into prostate cancer progression:the missing link of tumor microenvironment.J Urol,2005,173(6 pt 1):10-20.
[43]Zhu L,Lot WT,Cheng CW,et al.Possible predictive markers related to micrometastasis in breast cancer patients.Oncol Rep,2006,15(5):1217-1223.
[44]Kostopoulos I,Arapantoni-Dadioti P,Gogas H,et al.Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotHER-2/neuapy.Breast Cancer Res Treat,2006,96(3):251-261.
[45]Kim R,Arihiro K,Emi M,et,al.Potential role of HER-2 in primary breast tumor with bone metastasis.Oncol Rep,2006,15(6):1477-1484.
[46]Russell KS,Stem DE Polverini PJ,et al.Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis.AmJ Physiol,1999,277(6Pt2):H2205-H2211.
[47]Nakamura Y,Yasuoka H,Tsujimoto M,et al.Nitric oxide in breast cancer:induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.Clin Cancer Res,2006,12(4):1201-1207.
[48]Min C,Kirsch KH,Zhao Y,et al.The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of HER-2/neu-driven breast cancer.Cancer Res,2007,67(3):1105-1112.
[1]Ross JS,Fletcher JA.HER-2/neu(C-erb-B2)gene and protein in breast cancer.AmJ Clin Pthol,1999,112(1),53-67.
[2]Chunyou Cai,Zhi Yao.Activation of NF-κB in Human Breast Cancer and its Role in Cell Proliferation and Progresssion.Chinese Journal of Clinical Oncology,2006,3(1):5-10.
[3]Prenzel N,Fischer OM,Streit S,et al.The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.Endocr Relat Cancer,2001,8(1):11-31.
[4]Olayioye MA,Neve RM,Lane HA,et al.The ErbB signaling network:receptor heterodimerization in development and cancer.EMBO J,2000,19(13):3159-3167.
[5]Olayioye MA,Neve RM,Lane HA,et al.The ErbB signaling network:receptor heterodimerization in development and cancer.EMBO J,2000,19(13):3159-3167.
[6]Pauletti G,Godolphin W,Press MF,et al.Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.Oncogene,1996,13(1):63-72.
[7]Bargmann CI,Hung MC,Weinberg RA.Multiple independent activations of the neu oncogene by a point mutation altering the transmenbrane domain of p185.Cell,1986,45(5):649-657.
[8]Venter DJ,Tuzi NL,Kumar S,et al.Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas:immunohistological assessment correlates with gene amplification.Lancet,1987,2(8550):69-72.
[9]Ravdin PM,Chamness GC.The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer:a paradigm for the development of other macromolecular markers.Gene,1995,159(1):19-27.
[10]Samata A,Levea CM,Dougall WC,et al.Ligand and p185 density govern receptor interactions and tyrosine kinase ctivation.Proc Natl Acad Sci USA,1994,91(5):1711-1715.
[11]Reese DM,Slamon DJ.HER-2/neu signal transduction in human breast and ovarian cancer.Stem Cells,1997,15(1):1-8.
[12]Johnson GL,Vaillancourt RR.Sequential protein kianse reactions controlling cell growth and differentiation.Curr Opin Cell Biol,1994,6(2):230-238.
[13]Jones N,Dumont DJ.Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation.Curr Biol,1999,9(18):1057-1060.
[14]Shi ZQ,Yu DH,Park M,et al.Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.Mol Cell Biol,2000,20(5):1526-1536.
[15]Kato Y,Tapping RI,Huang S,et al.Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor.Nature,1998,395(6703):713-716.
[16]Datta SR,Brunet A,Greenberg ME.Cellular suvival:A play in three Akts.Genes Dev,1999,13(22):2905-2927.
[17]Downward J.Mechanisms and consequences of activation of protein kinase B/Akt.Curr Opin Cell Biol,1998,10(2):262-267.
[18]Zhou BP,Hung MC.Novel targets of Akt,p21(Cip1/WAF1),and MDM2.Semin Oncol,2002,29(3):62-70.
[19]Grossman SR,Perez M,Kung AL,et al.p300/MDM2 complexes participate in MDM2-mediated p53 degradation.Mol Cell,1998,2(4):405-415.
[20]Lin SY,Xia W,Wang JC,et al.Beta-catenin,a novel prognostic marker for breast cancer:its roles in cyclin D1 expression and cancer progression.Proc Natl Acad Sci USA,2000,97(8):4262-4266.
[21]Asada M,Yamada T,Ichijo H,et al.Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1)in monocytic differentiation.EMBO J,1999,18(5):1223-1234.
[22]Noh DY,Shin SH,Rhee SG.Phosphoinositide-specific phospholipase C and mitogenic signaling.Biochim Biophys Acta,1995,1242(2):99-113.
[23]Fazioli F,Kim U-H,Rhee S,et al.The erbB-2 mitogenic signaling pathway:tyrosine phosphorylation of phospholipase C-γ and GTP-ase activating protein does not correlate with erbB-2 mitogenic potency.Mol Cell Biol,1991,11(4):2040-2048.
[24]Makino K,Day CP,Wang SC,et al.Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER-2/neu-induced NF-kappaB antiapoptotic pathway.Oncogene,2004,23(21):3883-3887.
[25]Vogl G,Bartel H,Dietze O,etal.HER-2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.Appl Immunohistochem Mol Morphol,2006:14(2):138-145.
[26]Folkman J,Browder T,Palmblad J.Angiogenesis research:Guidelines for translation to clinical application.Thromb Haemost,2001,86(1):23-33.
[27]Wen XF,Yang G,Mao W,et al.HER-2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways:implications for HER-2-targeted antibody therapy.Oncogene,2006,25(52):6986-6996.
[28]Grothey A.Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.Semin Oncol,2006,33(5):41-49.
[29]Short SM,Yoder BJ,Tarr SM,et al.The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER-2 Overexpression and May Help Predict Response to Chemotherapy:A Retrospective Immunohistochemical Study.Breast J,2007,13(2):130-139.
[30]Russell KS,Stern DE Polverini PJ,etal.Neuregulin activation.of ErbB receptors in vascular endothelium leads to angiogenesis.AmJ Physiol,1999,277(6Pt2):H2205-2211.
[31]Carter WB.HER-2 signaling-induced micro vessel dismantling.Surgery,2001,130(2):382-387.
[32]Min C,Kirsch KH,Zhao Y,et al.The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of HER-2/neu-driven.breast cancer.Cancer Res,2007,67(3):1105-1112.
[33]Nakamura Y,Yasuoka H,Tsujimoto M,et al.Nitric oxide in breast cancer:induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.Clin Cancer Res,2006,12(4):1201-1207.
[34]Kim R,Arihiro K,Emi M,et,al.Potential role of HER-2 in primary breast tumor with bone metastasis.Oncol Rep,2006,15(6):1477-1484.
[35]Zhu L,Loo WT,Cheng CW,et al.Possible predictive markers related to micro-metastasis in breast cancer patients.Oncol Rep,2006,15(5):1217-1223.
[36]Kostopoulos I,Arapantoni-Dadioti P,Gogas H,et al.Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotHER-2/neuapy. Breast Cancer Res Treat, 2006,96(3): 251-261.
[37] Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 2007,18(6):1021-1029.
[38] Ciocca DR,Gago FE, Fanelli MA, et al.Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and HER-2/neu: Clinical implications. J Steroid Biochem Mol Biol, 2006,102(1-5): 32-40.
[39] Likhite VS, Stossi F, Kim K, et al. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol, 2006,20(12): 3120-3132.
[40] Johnston SR. Targeting downstream effectors of epidermal growth factor receptor/HER-2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int J Gynecol Cancer, 2006,16(2): 543-548.
[41] Dienstmann R, Bines J. Evidence-based neoadjuvant endocrine therapy for breast cancer. Clin Breast Cancer, 2006,7(4): 315-320.
[42] Ponzone R, Montemurro F, Maggiorotto F,et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol, 2006,17(11): 1631-1636.
[43] Okegawa T, Kinjo M, Nutahara K, et al.Pretreatment serum level of HER-2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol, 2006, 13(9): 1197-1201.
[44] Prowell TM, Armstrong DK.Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin Oncol, 2006, 33(6):681-687.
[45] Apostolaki S, Perraki M, Pallis A, et al. Circulating HER-2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol, 2007,18(5): 851-858.
[46] Tiezzi DG, Andrade JM, Ribeiro-Silva A,et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer, 2007, 26,7:36.
[47] Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer, 2007,111(2): 106-122.
[48] McHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotHER-2/neuapy regimens-evidence of schedule-dependent synergy. Urology, 2007,69(2): 390-394.
[49] Sauer R, Schauer A, Rauschecker HF.Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors. Int J Radiat Oncol Biol Phys, 1992,23(5): 907-914.
[50] Nakano T, Oka K, Ishikawa A.Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer. Cancer Detect Prev, 1998,22(2): 120-128.
[51] Ahmed KM, Cao N, Li JJ. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res, 2006, 26(6B) :4235-4243.
[52] Liang K, Lu Y, Jin W,et al.Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2003,2(11): 1113-1120.
[53] Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys, 2005,61(1): 203-211.
[54] Stackhouse MA, Buchsbaum DJ, Grizzle WE, et al.Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Int J Radiat Oncol Biol Phys, 1998,42(4): 817-822.
[55] Juranic ZD, Borojevic N, Jovanovic D,et al. Effects of X-ray irradiation on the overexpression of HER-2/Erb-B2 on breast cancer cell lines. J Exp Clin Cancer Res, 2004,23(4): 675-680.
[56] Dieras V, Vincent-Salomon A, Degeorges A,et al. Trastuzumab (HER-2/ neuceptin) and breast cancer: mechanisms of resistance. Bull Cancer, 2007, 94(3): 259-266.
[57] Xia W, Husain I, Liu L,et al.Lapatinib antitumor activity is not dependent upon Phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res, 2007,67(3): 1170-1175.
[58] Smith L Procter M, Gelber RD.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369(9555): 29-36.
[59] Kan N, Mise K, Moriguchi Y, et al.Stratification with respect to hormone receptor and HER-2/neu in the treatment of metastatic breast cancer; sensitivity to taxane.Gan To Kagaku Ryoho,2007,34(1):53-57.
[60]Ferretti G,Felici A,Papaldo P,et al.HER-2/neu role in breast cancer:from a prognostic foe to a predictive friend.Curr Opin Obstet Gynecol,2007,19(1):56-62.
[61]Kurian AW,Thompson RN,Gaw AF,et al.A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER-2/neu-positive breast cancer.J Clin Oncol,2007,25(6):634-641.
[62]Danova M,Giordano M,Torelli F,et al.HER-2/neu oncogene expression and DNA ploidy in normal human kidney and renal cell carcinoma.Eur J Histochem,1992,36(3):279-288.
[63]Herrera GA.C-erb B-2 amplification in cystic renal disease.Kidney Int,1991,40(3):509-513.
[64]Nakanishi K,Sweeney W Jr,Avner ED.Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease.J Am Soc Nephrol,2001,12(2):379-384.
[65]Salem M,Kinoshita Y,Tajiri T,et al.Association between the HER2 expression and histological differentiation in Wilms tumor.Pediatr Surg Int,2006,22(11):891-896.
[66]Tsai YS,Tzai TS,Chow NH,et al.Frequency and clinicopathologic correlates of ErbB1,ErbB2,and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract.Urology,2005,66(6):1197-1202.
[67]Imai T,Kimura M,Takeda M,et al.Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.Br J Cancer,1995,71(1):69-72.
[68]Hashimoto H,Sue Y,Tokumitsu M,et al.Overexpression of c-erbB-2 and p53oncoprotein in renal pelvic and ureteral carcinomas with reference to the expression of Ki-67 antigen as a proliferation marker.Nippon Hinyokika Gakkai Zasshi,1997,88(6):605-611.
[69]Stumm G,Eberwein S,Rostock-Wolf S,et al.Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma(RCC)is correlated with dedifferentiation and metastasis.Int J Cancer,1996,69(1):17-22.
[70]Tamaki M,Maeda S,Deguchi T,et al.Usefulness of DNA ploidy,AgNORs,PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma.Hinyokika Kiyo,1997,43(10):697-702.
[71] Seliger B, Rongcun Y, Atkins D, et al.HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer, 2000, 87(3): 349-359.
[72] Fontana LO, Garcia Garcia F, Arcas Martinez Salas I,et al.The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival. Arch Esp Urol, 2002,55(7):792-796.
[73] Lipponen P, Eskelinen M, Hietala K,et al. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int J Cancer, 1994, 57(2): 275-280.
[74] Langner C, Gross C, Rehak P,et al.HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology, 2005,65(1): 176-180.
[75] Latif Z, Watters AD, Bartlett JM,et al.Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int, 2002, 89(1): 5-9.
[76] Rasmuson T, Grankvist K, Ljungberg B.Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer, 1997,75(11): 1674-1677.
[77] Brossart P, Stuhler G, Flad T,et al.Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res, 1998, 58(4):732-736.
[78] Roth A, Rohrbach F, Weth R,et al.Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer, 2005,92(8):1421-1429.
[79] Rohrbach F, Weth R, Kursar M,et al.Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol, 2005,174(9): 5481-5489.
[80] Salem M, Kinoshita Y, Tajiri T,et al.Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr Surg Int, 2006, 22(11): 891- 896.
[81] Pinthus JH, Fridman E, Dekel B,et al.ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. J Urol, 2004,172(4): 1644-1648.
[82] Yokoi A, McCrudden KW, Huang J,et al.Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu- expressing experimental Wilms' tumor. J Pediatr Surg, 2003,38(11): 1569-1573.
[83] Yokoi A, McCrudden KW, Huang J,et al.Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep, 2003,10(5): 1271-1274.
[84] Pinthus JH, Sheffer Y, Nagler A, et al.Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol, 2005,174(4): 1527-1531.
[85] Eissa S, Ali HS, Al Tonsi AH, et al.HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem, 2005,38(2): 142-148.
[86] Coogan CL, Estrada CR, Kapur S,et al.HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology, 2004, 63(4): 786-790.
[87] Wulfing C, von Struensee D, Bierer S, et al.Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy. Aktuelle Urol, 2005, 36(5): 423-429.
[88] Gardmark T, Wester K, De la Torre M, et al.Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int, 2005, 95(7): 982-986.
[89] Amsellem-Ouazana D, Bieche I, Molinie V, et al.Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol, 2006,49(6): 1035-1042.
[90] Hauser-Kronberger C, Peham K, Grall J,et al.Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional ceU carcinoma of the bladder. J Urol, 2006,175(3 ): 875-880.
[91] Kruger S, Weitsch G, Buttner H, et al.HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer, 2002, 102(5): 514-518.
[92] Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer, 2002,95(5):1009-1015.
[93] Tsai YS, Tzai TS, Chow NH, et al.Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int, 2003,71(3):262-270.
[94] Raica M, Zylis D, Cimpean AM. Cytokeratin 20, 34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. Rom J Morphol Embryol, 2005,46(1): 11-5.
[95] Masliukova EA, Pozharisskii KM, Karelin MI, et al.Role of Ki-67, mutated gene-suppressor p53 and HER-2/neu oncoprotein in the prognosis for the clinical course of bladder cancer. Vopr Onkol, 2006,52(6):643-648.
[96] Kruger S, Mahnken A, Kausch I, et al.Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology, 2006, 67(1): 105-109.
[97] Latif Z, Watters AD, Dunn I,et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer, 2004,40(1): 56-63.
[98] Latif Z, Watters AD, Dunn I,et al.HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer, 2003, 89(7): 1305-1309.
[99] Kruger S, Weitsch G, Buttner H,et al.Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol, 2002, 21(5): 981-987.
[100] Memon AA, Sorensen BS, Meldgaard P, et al.The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer, 2006,94(11): 1703-1709.
[101] Eltze E, Wulfing C, Von Struensee D, et al.Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol, 2005,26(6):1525-1531.
[102] Montironi R, Mazzucchelli R, Barbisan F, et al.HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol, 2006,37 (9):1137-1144.
[103] Nishio Y, Yamada Y, Kokubo H,et al.Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology, 2006,68(1):110-115.
[104] Wang X, Jones TD, Zhang S,et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol, 2007,20(2): 175-182.
[105] Murphy AJ, Hughes CA, Barrett C,et al.Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res, 2007,67(6):2893-2898.
[106] Yamada Y, Nakamura K, Aoki S,et al.An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer. BJU Int, 2007,99(1):189-195.
[107] Edwards J, Traynor P,Munro AF,et al.The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res, 2006,12(1): 123-130.
[108] Osman I, Mikhail M, Shuch B,et al.Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol, 2005, 174(6): 2174-2177.
[109] Okegawa T, Kinjo M, Nutahara K, et al.Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol, 2006,13(9):1197-1201.
[110] Shi Y, Chatterjee SJ, Brands FH, et al. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int, 2006,97(1): 170-178.
[111] Le Page C, Koumakpayi IH, Lessard L,et al.Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2- mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate, 2005, 65(4): 306-315.
[112] Liu Y, Majumder S, McCall W, et al.Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res, 2005, 65(8): 3404-3409.
[113] Agus DB, Sweeney CJ, Morris MJ,et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol, 2007,25(6):675-681.
[114] Legrier ME, Oudard S, Judde JG, et al.Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer, 2007,96(2):269-276.
[115] Hueman MT, Dehqanzada ZA, Novak TE,et al.Phase I clinical trial of a HER-2/ neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res, 2005,11(20):7470-7479
[116]Mandoky L,Geczi L,Bodrogi I,et al.Expression of HER-2/neu in testicular tumors.Anticancer Res,2003,23(4):3447-3451.
[117]Moroni M,Veronese S,Schiavo R,et al.Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.Clin Cancer Res,2001,7(9):2770-2775.
[118]Mandoky L,Geczi L,Bodrogi I,et al.Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.Anticancer Res,2004,24(4):2219-2224.
[119]Soule S,Baldridge L,Kirkpatrick K,et al.HER-2/neu expression in germ cell tumours.J Clin Pathol,2002,55(9):656-658.
[1]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cell.Nature,2000,404(6775):293-296.
[2]Nykanen A,Haley B,Zamore PD.ATP requirements and small interfering RNA structuire in the RNA interference pathway.Cell,2001,107(3):309-21.
[3]Elbashir SM,Martinez J,Patkaniowska A,et al.Furetional anatomy of siRNAs for mediating eflicient RNAi in Drosophila melanogaster embryo Lysate.EMBO J,2001,(20):6877-6888.
[4]Gil J,Esteban M.Induction of apoptosis by the dsRNA2dependent protein kinase (PKR):mechanism of action.Apoptosis,2000,5(2):107-114.
[5]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[6] Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004,432 (7014): 173- 178.
[7] Sioud M. Therapeutic siRNAs .Trends Pharmacol Sci, 2004,25 (1): 22-28.
[8] Miyagishi M, Taira K. U6 promoter -driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol, 2002,20 (5): 497-500.
[9] Brurnmelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002,296(5567): 550-553.
[10] Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 2003 ,9(4): 493-501.
[11] Zamore PD, Aronin N. siRNAs knock down hepatitis. Nat Med, 2003, 9 (3): 266-267.
[12] Scherr M , Steinmann D , Eder M. RNA interference (RNAi) in hematology. Ann Hematol. 2004, 83(1): 1-8.
[13] Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today. 2006 ,11(1-2):67-73.
[14] Wang C, Navab R, Iakovlev V,et al. Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol Cancer Res, 2007,5(10): 1031-1039.
[15] Zhang Y, Wang ZN, Zhang X, et al. Inhibitory effect of siRNA on heparanase expression and invasion ability of gastric cancer cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi, 2007,87(24):1717-1720.
[16] Christensen HS, Daher A, Soye KJ, et al.Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J Virol, 2007, 81(10): 5121-5131.
[17] Takano Y, Shimokado K, Hata Y,et al. HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta, 2007,1772(5): 549-555.
[18] Nagai Y, Popiel HA, Fujikake N, et al. Therapeutic strategies for the polyglutamine diseases. Brain Nerve, 2007,59(4):393-404.
[19] Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res, 2004, 2(2): 89-95.
[20] Petrella BL, Brinckerhoff CE. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.Mol Cancer, 2006 Dec 1;5:66.
[21] Lin PY, Fosmire SP, Park SH,et al. Attenuation of PTEN increases p21 stability and Cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance.Mol Cancer, 2007 Feb 14;6:16.
[22] Crnkovic-Mertens I, Wagener N, Semzow J,et al. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis.Cell Mol Life Sci, 2007, 64(9): 1137 -1144.
[23] Zheng JN, Sun YF, Pei DS, et al. Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs.Acta Biochim Biophys Sin (Shanghai), 2006, 38(7):500-506.
[24] Sato A, Oya M, Ito K, et al. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.Int J Oncol, 2006,28(4):841-846.
[25] Cascon A, Escobar B, Montero-Conde C,et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat, 2007,28(6): 613-621.
[26] Sauermann M, Sahin O, Sultmann H, et al. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells. Oncogene, 2008, 27(9):1320-1326.
[27] Xu L, Tong R, Cochran DM, et al. Blocking platelet-derived growth factor-D/ platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.Cancer Res, 2005, 65(13): 5711 -5719.
[28] Pan J, Mestas J, Burdick MD, Phillips RJ,et al. Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer, 2006 Nov 3;5:56.
[29] Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res, 2004, 64(14): 4833-4840.
[30] Zou L, Zhang P, Luo C, et al. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity.Cancer Chemother Pharmacol. 2006,57(3):328-334.
[31] Wu F, Chen Y, Li Y,et al. RNA interference-mediated Cdc42 silencing downregulates phosphorylation of STAT3 and suppresses growth in human bladder cancer cells.Biotechnol Appl Biochem, 2008,49(Pt 2): 121-128.
[32] Nogawa M, Yuasa T, Kimura S, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest, 2005,115(4): 978-985.
[33] Ning S, Fuessel S, Kotzsch M,et al. siRNA-mediated down-regulation of surviving inhibits bladder cancer cell growth. Int J Oncol, 2004,25(4): 1065-1071.
[34] Yang SM, Wen DG, Hou JQ,et al. Establishment and application of an orthotopic murine bladder cancer model. Ai Zheng, 2007,26(4):341-345.
[35] Cho HJ, Kim JK, Kim KD,et al. Upregulation of Bcl-2 is associated with cisplatin- resistance via inhibition of Bax translocation in human bladder cancer cells.Cancer Lett, 2006 ,237(1):56-66.
[36] Tararova ND, Narizhneva N, Krivokrisenko V,et al. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate, 2007, 67(16): 1801-1815.
[37] Xu XF, Zhang ZY, Ge JP, et al. RNA interference-mediated silencing of the PAR gene inhibits the growth of PC3 cells via the induction of G2/M cell cycle arrest and apoptosis. J Gene Med, 2007,9(12): 1065-1070.
[38] Stettner M, Kaulfuss S, Burfeind P,et al. The relevance of estrogen receptor- {beta} expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther, 2007, 6(10): 2626-2633.
[39] Thelen P, Burfeind P, Schweyer S,et al. Molecular principles of alternative treatment approaches for hormone-refractory prostate cancer. Urologe A, 2007,46(9): 1271-1274.
[40] Sahadevan K, Darby S, Leung HY,et al. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol, 2007, 213(1): 82- 90.
[41] Zhang L, Gao L, Zhao L,et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res, 2007,67(12):5859-5864.
[42] El Touny LH, Banerjee PP. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun, 2007, 361(1):169-175.
[43] Spierings DC, de Vries EG, Stel AJ,et al. Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene, 2004, 23(28): 4862-4872.
[44] Lee JH, Schutte D, Wulf G,et al. Stem-cell protein Piwi12 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet, 2006,15(2): 201-211.
[45] Minakuchi Y, Takeshita F, Kosaka N,et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res, 2004,32(13):e109.
[2]Kwak C,Ku JH,Park JY,et al.Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T_1 Grade 3 bladder cancer.Joural of Urology,2004(1):149-152.
[3]苏定冯,缪朝玉,王永铭。2003药理学进展。北京:人民卫生出版社,2003。46。
[4]Yoshikawa D,Ojima H,Iwasaki M,et al.Clinicopathological and prognostic significance of EGFR,VEGF,and HER2 expression in cholangiocarcinoma,2008,98(2):418-425.
[5]Barnes DM,Meyer JS,Gonzalez JG,et al.Relationship between cerb-B2immunoreactivity and thymidine labeling index in breast carcinoma in situ.Breast Cancer Res Treat,1991,18(1):11-17.
[6]Zhong W,Peng J,He H,et al.Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia,2008,31(1):ES-E15.
[7]Pinkas-Kramarski R,Soussan L,Waterman H,et al.Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions,1996,15(10):2452-2467.
[8]Amsellem-Ouazana D,Bieche I,Molinie V,et al.Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol,2006,49(6):1035-1042.
[9]Hauser-Kronberger C,Peham K,Grall J,et al.Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder.J Urol,2006,175(3):875-880.
[10]Coogan CL,Estrada CR,Kapur S,et al..HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.Urology,2004,63(4):786-790.
[11]Wulfing C,von Struensee D,Bierer S,et al.Expression of Her2/neu in locally advanced bladder cancer:implication for a molecular targeted therapy.Aktuelle Urol,2005,36(5):423-429.
[12]Gardmark T,Wester K,De la Torre M,et al.Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.BJU Int,2005,95(7):982-986.
[13]Lake-Bakaar G,Mazzoccoli V,Ruffini L.Digital image analysis of the distribution of proliferating cell muclear antigen in hepatitis C virus relates chronic hepatitis,crirrhosis,and hepatocellular carcinoma.Dig Dis Sci,2002,47(7):1644-1648.
[14]Tsujihashi H,Nakanishi A,Matsuda H,et al.Cell proliferation of human bladder tumors determined by BRDURD and Ki-67immunostaining.J Urol,1991,145(4):846-849.
[15]Vogl G,Bartel H,Dietze O,etal.HER-2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.Appl Immunohistochem Mol Morphol,2006:14(2):138-145.
[16]Folkman J,Browder T,Palmblad J.Angiogenesis research:Guidelines for translation to clinical application.Thromb Haemost,2001,86(1):23-33.
[17]Wen XF,Yang G,Mao W,et al.HER-2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways:implications for HER-2-targeted antibody therapy.Oncogene,2006,25(52):6986-6996.
[18]Grothey A.Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.Semin Oncol,2006,33(5):41-49.
[19]Carter WB.HER-2 signaling-induced micro vessel dismantling.Surgery,2001,130(2):382-387.
[20]Tsai YS,Tzai TS,Chow NH.Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol hat,2007,79(3):210-216.
[21]Nakano T,Oka K,Ishikawa A.Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer.Cancer Detect Prev,1998,22(2):120-128.
[22]Colomer R,Llombart-Cussac A,Lloveras B,et al.High circulating HER2extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer:A confirmatory prospective study.Cancer,2007,110(10):2178-2185.
[23]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cell.Nature,2000,404(6775):293-296.
[24]Elbashir SM,Martinez J,Patkaniowska A,et al.Furetional anatomy of siRNAs for mediating eflicient RNAi in Drosophila melanogaster embryo Lysate.EMBO J,2001,20(23):6877-6888.
[25]Reynolds A,Leake D,Boese Q,et al.Rational siRNA design for RNA interference.,2004,22(3):326-330.
[26]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[27]Soutschek J,Akinc A,Bramlage B,et al.Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.Nature,2004,432(7014):173-178.
[28]Raica M,Zylis D,Cimpean AM.Cytokeratin 20,34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma.Rom J Morphol Embryol,2005,46(1):11-15.
[29]Masliukova EA,Pozharisskii KM,Karelin MI,et al.Role of Ki-67,mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer.Vopr Onkol,2006,52(6):643-648.
[30]Papazisis KT,Habeshaw T,Miles DW,et,al.Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer.A review of the existing clinical trials and results of the expanded access programme in the UK.Int J Clin Pract,2004.58(6):581-586.
[31]Graus-Porta D,Beerli RR,Hynes NE.Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.Mol Cell Biol,1995,15(3):1182-1191.
[32]邱学德,刘乔保,王田等。酪氨酸激酶抑制剂PD168393对HER2不同表达水平膀胱癌细胞株的作用研究。中华肿瘤防治杂志,2006,13(8):604-607。
[33]Nagasawa J,Mizokami A,Koshida K,et al.Novel HER2 selective tyrosine kinase inhibitor,TAK-165,inhibits bladder,kidney and androgen-independent prostate cancer in vitro and in vivo.hat J Urol,2006,13(5):587-592.
[34]Miyagishi M,Taira K.U6 promoter-driven siRNAs with four uridine 3'overhangs efficiently suppress targeted gene expression in mammalian cells.Nat Biotechnol,2002,20(5):497-500.
[35]Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296(5567):550-553.
[36]Bernstein E,Caudy AA,Hammond SM,et al.Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature,2001,409(6818):363-366.
[37]Hannon GJ.RNA interference.Nature,2002,418(6894):244-251.
[38]Nykanen A,Haley B,Zamore PD.ATP requirements and small interfering RNA structuire in the RNA interference pathway.Cell,2001,107(3):309-321.
[39]Zamore PD.RNA interference:listening to the sound of silence.Nat Struct Biol,2001,8(9):746-750.
[40]Akiyama S,Furukawa T,Sumizawa T,et al.The role of thymidine phosphorylase,an angiogenic enzyme,in tumor progression.Cancer Sci,2004,95(11):851-857.
[41]Awwad RA,Sergina N,Yang H,et al.The role of transforming growth factor alpha in determining growth factor independence.Cancer Res,2003,63(15):4731-4738.
[42]Chung LW,Baseman A,Ass ikis V,et al.Molecular insights into prostate cancer progression:the missing link of tumor microenvironment.J Urol,2005,173(6 pt 1):10-20.
[43]Zhu L,Lot WT,Cheng CW,et al.Possible predictive markers related to micrometastasis in breast cancer patients.Oncol Rep,2006,15(5):1217-1223.
[44]Kostopoulos I,Arapantoni-Dadioti P,Gogas H,et al.Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotHER-2/neuapy.Breast Cancer Res Treat,2006,96(3):251-261.
[45]Kim R,Arihiro K,Emi M,et,al.Potential role of HER-2 in primary breast tumor with bone metastasis.Oncol Rep,2006,15(6):1477-1484.
[46]Russell KS,Stem DE Polverini PJ,et al.Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis.AmJ Physiol,1999,277(6Pt2):H2205-H2211.
[47]Nakamura Y,Yasuoka H,Tsujimoto M,et al.Nitric oxide in breast cancer:induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.Clin Cancer Res,2006,12(4):1201-1207.
[48]Min C,Kirsch KH,Zhao Y,et al.The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of HER-2/neu-driven breast cancer.Cancer Res,2007,67(3):1105-1112.
[1]Ross JS,Fletcher JA.HER-2/neu(C-erb-B2)gene and protein in breast cancer.AmJ Clin Pthol,1999,112(1),53-67.
[2]Chunyou Cai,Zhi Yao.Activation of NF-κB in Human Breast Cancer and its Role in Cell Proliferation and Progresssion.Chinese Journal of Clinical Oncology,2006,3(1):5-10.
[3]Prenzel N,Fischer OM,Streit S,et al.The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.Endocr Relat Cancer,2001,8(1):11-31.
[4]Olayioye MA,Neve RM,Lane HA,et al.The ErbB signaling network:receptor heterodimerization in development and cancer.EMBO J,2000,19(13):3159-3167.
[5]Olayioye MA,Neve RM,Lane HA,et al.The ErbB signaling network:receptor heterodimerization in development and cancer.EMBO J,2000,19(13):3159-3167.
[6]Pauletti G,Godolphin W,Press MF,et al.Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.Oncogene,1996,13(1):63-72.
[7]Bargmann CI,Hung MC,Weinberg RA.Multiple independent activations of the neu oncogene by a point mutation altering the transmenbrane domain of p185.Cell,1986,45(5):649-657.
[8]Venter DJ,Tuzi NL,Kumar S,et al.Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas:immunohistological assessment correlates with gene amplification.Lancet,1987,2(8550):69-72.
[9]Ravdin PM,Chamness GC.The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer:a paradigm for the development of other macromolecular markers.Gene,1995,159(1):19-27.
[10]Samata A,Levea CM,Dougall WC,et al.Ligand and p185 density govern receptor interactions and tyrosine kinase ctivation.Proc Natl Acad Sci USA,1994,91(5):1711-1715.
[11]Reese DM,Slamon DJ.HER-2/neu signal transduction in human breast and ovarian cancer.Stem Cells,1997,15(1):1-8.
[12]Johnson GL,Vaillancourt RR.Sequential protein kianse reactions controlling cell growth and differentiation.Curr Opin Cell Biol,1994,6(2):230-238.
[13]Jones N,Dumont DJ.Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation.Curr Biol,1999,9(18):1057-1060.
[14]Shi ZQ,Yu DH,Park M,et al.Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.Mol Cell Biol,2000,20(5):1526-1536.
[15]Kato Y,Tapping RI,Huang S,et al.Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor.Nature,1998,395(6703):713-716.
[16]Datta SR,Brunet A,Greenberg ME.Cellular suvival:A play in three Akts.Genes Dev,1999,13(22):2905-2927.
[17]Downward J.Mechanisms and consequences of activation of protein kinase B/Akt.Curr Opin Cell Biol,1998,10(2):262-267.
[18]Zhou BP,Hung MC.Novel targets of Akt,p21(Cip1/WAF1),and MDM2.Semin Oncol,2002,29(3):62-70.
[19]Grossman SR,Perez M,Kung AL,et al.p300/MDM2 complexes participate in MDM2-mediated p53 degradation.Mol Cell,1998,2(4):405-415.
[20]Lin SY,Xia W,Wang JC,et al.Beta-catenin,a novel prognostic marker for breast cancer:its roles in cyclin D1 expression and cancer progression.Proc Natl Acad Sci USA,2000,97(8):4262-4266.
[21]Asada M,Yamada T,Ichijo H,et al.Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1)in monocytic differentiation.EMBO J,1999,18(5):1223-1234.
[22]Noh DY,Shin SH,Rhee SG.Phosphoinositide-specific phospholipase C and mitogenic signaling.Biochim Biophys Acta,1995,1242(2):99-113.
[23]Fazioli F,Kim U-H,Rhee S,et al.The erbB-2 mitogenic signaling pathway:tyrosine phosphorylation of phospholipase C-γ and GTP-ase activating protein does not correlate with erbB-2 mitogenic potency.Mol Cell Biol,1991,11(4):2040-2048.
[24]Makino K,Day CP,Wang SC,et al.Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER-2/neu-induced NF-kappaB antiapoptotic pathway.Oncogene,2004,23(21):3883-3887.
[25]Vogl G,Bartel H,Dietze O,etal.HER-2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.Appl Immunohistochem Mol Morphol,2006:14(2):138-145.
[26]Folkman J,Browder T,Palmblad J.Angiogenesis research:Guidelines for translation to clinical application.Thromb Haemost,2001,86(1):23-33.
[27]Wen XF,Yang G,Mao W,et al.HER-2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways:implications for HER-2-targeted antibody therapy.Oncogene,2006,25(52):6986-6996.
[28]Grothey A.Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.Semin Oncol,2006,33(5):41-49.
[29]Short SM,Yoder BJ,Tarr SM,et al.The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER-2 Overexpression and May Help Predict Response to Chemotherapy:A Retrospective Immunohistochemical Study.Breast J,2007,13(2):130-139.
[30]Russell KS,Stern DE Polverini PJ,etal.Neuregulin activation.of ErbB receptors in vascular endothelium leads to angiogenesis.AmJ Physiol,1999,277(6Pt2):H2205-2211.
[31]Carter WB.HER-2 signaling-induced micro vessel dismantling.Surgery,2001,130(2):382-387.
[32]Min C,Kirsch KH,Zhao Y,et al.The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of HER-2/neu-driven.breast cancer.Cancer Res,2007,67(3):1105-1112.
[33]Nakamura Y,Yasuoka H,Tsujimoto M,et al.Nitric oxide in breast cancer:induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.Clin Cancer Res,2006,12(4):1201-1207.
[34]Kim R,Arihiro K,Emi M,et,al.Potential role of HER-2 in primary breast tumor with bone metastasis.Oncol Rep,2006,15(6):1477-1484.
[35]Zhu L,Loo WT,Cheng CW,et al.Possible predictive markers related to micro-metastasis in breast cancer patients.Oncol Rep,2006,15(5):1217-1223.
[36]Kostopoulos I,Arapantoni-Dadioti P,Gogas H,et al.Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotHER-2/neuapy. Breast Cancer Res Treat, 2006,96(3): 251-261.
[37] Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 2007,18(6):1021-1029.
[38] Ciocca DR,Gago FE, Fanelli MA, et al.Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and HER-2/neu: Clinical implications. J Steroid Biochem Mol Biol, 2006,102(1-5): 32-40.
[39] Likhite VS, Stossi F, Kim K, et al. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol, 2006,20(12): 3120-3132.
[40] Johnston SR. Targeting downstream effectors of epidermal growth factor receptor/HER-2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int J Gynecol Cancer, 2006,16(2): 543-548.
[41] Dienstmann R, Bines J. Evidence-based neoadjuvant endocrine therapy for breast cancer. Clin Breast Cancer, 2006,7(4): 315-320.
[42] Ponzone R, Montemurro F, Maggiorotto F,et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol, 2006,17(11): 1631-1636.
[43] Okegawa T, Kinjo M, Nutahara K, et al.Pretreatment serum level of HER-2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol, 2006, 13(9): 1197-1201.
[44] Prowell TM, Armstrong DK.Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin Oncol, 2006, 33(6):681-687.
[45] Apostolaki S, Perraki M, Pallis A, et al. Circulating HER-2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol, 2007,18(5): 851-858.
[46] Tiezzi DG, Andrade JM, Ribeiro-Silva A,et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer, 2007, 26,7:36.
[47] Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer, 2007,111(2): 106-122.
[48] McHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotHER-2/neuapy regimens-evidence of schedule-dependent synergy. Urology, 2007,69(2): 390-394.
[49] Sauer R, Schauer A, Rauschecker HF.Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors. Int J Radiat Oncol Biol Phys, 1992,23(5): 907-914.
[50] Nakano T, Oka K, Ishikawa A.Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer. Cancer Detect Prev, 1998,22(2): 120-128.
[51] Ahmed KM, Cao N, Li JJ. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res, 2006, 26(6B) :4235-4243.
[52] Liang K, Lu Y, Jin W,et al.Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2003,2(11): 1113-1120.
[53] Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys, 2005,61(1): 203-211.
[54] Stackhouse MA, Buchsbaum DJ, Grizzle WE, et al.Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Int J Radiat Oncol Biol Phys, 1998,42(4): 817-822.
[55] Juranic ZD, Borojevic N, Jovanovic D,et al. Effects of X-ray irradiation on the overexpression of HER-2/Erb-B2 on breast cancer cell lines. J Exp Clin Cancer Res, 2004,23(4): 675-680.
[56] Dieras V, Vincent-Salomon A, Degeorges A,et al. Trastuzumab (HER-2/ neuceptin) and breast cancer: mechanisms of resistance. Bull Cancer, 2007, 94(3): 259-266.
[57] Xia W, Husain I, Liu L,et al.Lapatinib antitumor activity is not dependent upon Phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res, 2007,67(3): 1170-1175.
[58] Smith L Procter M, Gelber RD.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369(9555): 29-36.
[59] Kan N, Mise K, Moriguchi Y, et al.Stratification with respect to hormone receptor and HER-2/neu in the treatment of metastatic breast cancer; sensitivity to taxane.Gan To Kagaku Ryoho,2007,34(1):53-57.
[60]Ferretti G,Felici A,Papaldo P,et al.HER-2/neu role in breast cancer:from a prognostic foe to a predictive friend.Curr Opin Obstet Gynecol,2007,19(1):56-62.
[61]Kurian AW,Thompson RN,Gaw AF,et al.A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER-2/neu-positive breast cancer.J Clin Oncol,2007,25(6):634-641.
[62]Danova M,Giordano M,Torelli F,et al.HER-2/neu oncogene expression and DNA ploidy in normal human kidney and renal cell carcinoma.Eur J Histochem,1992,36(3):279-288.
[63]Herrera GA.C-erb B-2 amplification in cystic renal disease.Kidney Int,1991,40(3):509-513.
[64]Nakanishi K,Sweeney W Jr,Avner ED.Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease.J Am Soc Nephrol,2001,12(2):379-384.
[65]Salem M,Kinoshita Y,Tajiri T,et al.Association between the HER2 expression and histological differentiation in Wilms tumor.Pediatr Surg Int,2006,22(11):891-896.
[66]Tsai YS,Tzai TS,Chow NH,et al.Frequency and clinicopathologic correlates of ErbB1,ErbB2,and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract.Urology,2005,66(6):1197-1202.
[67]Imai T,Kimura M,Takeda M,et al.Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.Br J Cancer,1995,71(1):69-72.
[68]Hashimoto H,Sue Y,Tokumitsu M,et al.Overexpression of c-erbB-2 and p53oncoprotein in renal pelvic and ureteral carcinomas with reference to the expression of Ki-67 antigen as a proliferation marker.Nippon Hinyokika Gakkai Zasshi,1997,88(6):605-611.
[69]Stumm G,Eberwein S,Rostock-Wolf S,et al.Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma(RCC)is correlated with dedifferentiation and metastasis.Int J Cancer,1996,69(1):17-22.
[70]Tamaki M,Maeda S,Deguchi T,et al.Usefulness of DNA ploidy,AgNORs,PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma.Hinyokika Kiyo,1997,43(10):697-702.
[71] Seliger B, Rongcun Y, Atkins D, et al.HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer, 2000, 87(3): 349-359.
[72] Fontana LO, Garcia Garcia F, Arcas Martinez Salas I,et al.The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival. Arch Esp Urol, 2002,55(7):792-796.
[73] Lipponen P, Eskelinen M, Hietala K,et al. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int J Cancer, 1994, 57(2): 275-280.
[74] Langner C, Gross C, Rehak P,et al.HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology, 2005,65(1): 176-180.
[75] Latif Z, Watters AD, Bartlett JM,et al.Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int, 2002, 89(1): 5-9.
[76] Rasmuson T, Grankvist K, Ljungberg B.Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer, 1997,75(11): 1674-1677.
[77] Brossart P, Stuhler G, Flad T,et al.Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res, 1998, 58(4):732-736.
[78] Roth A, Rohrbach F, Weth R,et al.Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer, 2005,92(8):1421-1429.
[79] Rohrbach F, Weth R, Kursar M,et al.Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol, 2005,174(9): 5481-5489.
[80] Salem M, Kinoshita Y, Tajiri T,et al.Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr Surg Int, 2006, 22(11): 891- 896.
[81] Pinthus JH, Fridman E, Dekel B,et al.ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. J Urol, 2004,172(4): 1644-1648.
[82] Yokoi A, McCrudden KW, Huang J,et al.Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu- expressing experimental Wilms' tumor. J Pediatr Surg, 2003,38(11): 1569-1573.
[83] Yokoi A, McCrudden KW, Huang J,et al.Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep, 2003,10(5): 1271-1274.
[84] Pinthus JH, Sheffer Y, Nagler A, et al.Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol, 2005,174(4): 1527-1531.
[85] Eissa S, Ali HS, Al Tonsi AH, et al.HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem, 2005,38(2): 142-148.
[86] Coogan CL, Estrada CR, Kapur S,et al.HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology, 2004, 63(4): 786-790.
[87] Wulfing C, von Struensee D, Bierer S, et al.Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy. Aktuelle Urol, 2005, 36(5): 423-429.
[88] Gardmark T, Wester K, De la Torre M, et al.Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int, 2005, 95(7): 982-986.
[89] Amsellem-Ouazana D, Bieche I, Molinie V, et al.Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol, 2006,49(6): 1035-1042.
[90] Hauser-Kronberger C, Peham K, Grall J,et al.Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional ceU carcinoma of the bladder. J Urol, 2006,175(3 ): 875-880.
[91] Kruger S, Weitsch G, Buttner H, et al.HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer, 2002, 102(5): 514-518.
[92] Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer, 2002,95(5):1009-1015.
[93] Tsai YS, Tzai TS, Chow NH, et al.Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int, 2003,71(3):262-270.
[94] Raica M, Zylis D, Cimpean AM. Cytokeratin 20, 34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. Rom J Morphol Embryol, 2005,46(1): 11-5.
[95] Masliukova EA, Pozharisskii KM, Karelin MI, et al.Role of Ki-67, mutated gene-suppressor p53 and HER-2/neu oncoprotein in the prognosis for the clinical course of bladder cancer. Vopr Onkol, 2006,52(6):643-648.
[96] Kruger S, Mahnken A, Kausch I, et al.Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology, 2006, 67(1): 105-109.
[97] Latif Z, Watters AD, Dunn I,et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer, 2004,40(1): 56-63.
[98] Latif Z, Watters AD, Dunn I,et al.HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer, 2003, 89(7): 1305-1309.
[99] Kruger S, Weitsch G, Buttner H,et al.Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol, 2002, 21(5): 981-987.
[100] Memon AA, Sorensen BS, Meldgaard P, et al.The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer, 2006,94(11): 1703-1709.
[101] Eltze E, Wulfing C, Von Struensee D, et al.Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol, 2005,26(6):1525-1531.
[102] Montironi R, Mazzucchelli R, Barbisan F, et al.HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol, 2006,37 (9):1137-1144.
[103] Nishio Y, Yamada Y, Kokubo H,et al.Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology, 2006,68(1):110-115.
[104] Wang X, Jones TD, Zhang S,et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol, 2007,20(2): 175-182.
[105] Murphy AJ, Hughes CA, Barrett C,et al.Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res, 2007,67(6):2893-2898.
[106] Yamada Y, Nakamura K, Aoki S,et al.An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer. BJU Int, 2007,99(1):189-195.
[107] Edwards J, Traynor P,Munro AF,et al.The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res, 2006,12(1): 123-130.
[108] Osman I, Mikhail M, Shuch B,et al.Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol, 2005, 174(6): 2174-2177.
[109] Okegawa T, Kinjo M, Nutahara K, et al.Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol, 2006,13(9):1197-1201.
[110] Shi Y, Chatterjee SJ, Brands FH, et al. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int, 2006,97(1): 170-178.
[111] Le Page C, Koumakpayi IH, Lessard L,et al.Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2- mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate, 2005, 65(4): 306-315.
[112] Liu Y, Majumder S, McCall W, et al.Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res, 2005, 65(8): 3404-3409.
[113] Agus DB, Sweeney CJ, Morris MJ,et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol, 2007,25(6):675-681.
[114] Legrier ME, Oudard S, Judde JG, et al.Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer, 2007,96(2):269-276.
[115] Hueman MT, Dehqanzada ZA, Novak TE,et al.Phase I clinical trial of a HER-2/ neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res, 2005,11(20):7470-7479
[116]Mandoky L,Geczi L,Bodrogi I,et al.Expression of HER-2/neu in testicular tumors.Anticancer Res,2003,23(4):3447-3451.
[117]Moroni M,Veronese S,Schiavo R,et al.Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.Clin Cancer Res,2001,7(9):2770-2775.
[118]Mandoky L,Geczi L,Bodrogi I,et al.Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.Anticancer Res,2004,24(4):2219-2224.
[119]Soule S,Baldridge L,Kirkpatrick K,et al.HER-2/neu expression in germ cell tumours.J Clin Pathol,2002,55(9):656-658.
[1]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cell.Nature,2000,404(6775):293-296.
[2]Nykanen A,Haley B,Zamore PD.ATP requirements and small interfering RNA structuire in the RNA interference pathway.Cell,2001,107(3):309-21.
[3]Elbashir SM,Martinez J,Patkaniowska A,et al.Furetional anatomy of siRNAs for mediating eflicient RNAi in Drosophila melanogaster embryo Lysate.EMBO J,2001,(20):6877-6888.
[4]Gil J,Esteban M.Induction of apoptosis by the dsRNA2dependent protein kinase (PKR):mechanism of action.Apoptosis,2000,5(2):107-114.
[5]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[6] Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004,432 (7014): 173- 178.
[7] Sioud M. Therapeutic siRNAs .Trends Pharmacol Sci, 2004,25 (1): 22-28.
[8] Miyagishi M, Taira K. U6 promoter -driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol, 2002,20 (5): 497-500.
[9] Brurnmelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002,296(5567): 550-553.
[10] Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 2003 ,9(4): 493-501.
[11] Zamore PD, Aronin N. siRNAs knock down hepatitis. Nat Med, 2003, 9 (3): 266-267.
[12] Scherr M , Steinmann D , Eder M. RNA interference (RNAi) in hematology. Ann Hematol. 2004, 83(1): 1-8.
[13] Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today. 2006 ,11(1-2):67-73.
[14] Wang C, Navab R, Iakovlev V,et al. Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol Cancer Res, 2007,5(10): 1031-1039.
[15] Zhang Y, Wang ZN, Zhang X, et al. Inhibitory effect of siRNA on heparanase expression and invasion ability of gastric cancer cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi, 2007,87(24):1717-1720.
[16] Christensen HS, Daher A, Soye KJ, et al.Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J Virol, 2007, 81(10): 5121-5131.
[17] Takano Y, Shimokado K, Hata Y,et al. HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta, 2007,1772(5): 549-555.
[18] Nagai Y, Popiel HA, Fujikake N, et al. Therapeutic strategies for the polyglutamine diseases. Brain Nerve, 2007,59(4):393-404.
[19] Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res, 2004, 2(2): 89-95.
[20] Petrella BL, Brinckerhoff CE. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.Mol Cancer, 2006 Dec 1;5:66.
[21] Lin PY, Fosmire SP, Park SH,et al. Attenuation of PTEN increases p21 stability and Cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance.Mol Cancer, 2007 Feb 14;6:16.
[22] Crnkovic-Mertens I, Wagener N, Semzow J,et al. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis.Cell Mol Life Sci, 2007, 64(9): 1137 -1144.
[23] Zheng JN, Sun YF, Pei DS, et al. Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs.Acta Biochim Biophys Sin (Shanghai), 2006, 38(7):500-506.
[24] Sato A, Oya M, Ito K, et al. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.Int J Oncol, 2006,28(4):841-846.
[25] Cascon A, Escobar B, Montero-Conde C,et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat, 2007,28(6): 613-621.
[26] Sauermann M, Sahin O, Sultmann H, et al. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells. Oncogene, 2008, 27(9):1320-1326.
[27] Xu L, Tong R, Cochran DM, et al. Blocking platelet-derived growth factor-D/ platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.Cancer Res, 2005, 65(13): 5711 -5719.
[28] Pan J, Mestas J, Burdick MD, Phillips RJ,et al. Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer, 2006 Nov 3;5:56.
[29] Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res, 2004, 64(14): 4833-4840.
[30] Zou L, Zhang P, Luo C, et al. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity.Cancer Chemother Pharmacol. 2006,57(3):328-334.
[31] Wu F, Chen Y, Li Y,et al. RNA interference-mediated Cdc42 silencing downregulates phosphorylation of STAT3 and suppresses growth in human bladder cancer cells.Biotechnol Appl Biochem, 2008,49(Pt 2): 121-128.
[32] Nogawa M, Yuasa T, Kimura S, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest, 2005,115(4): 978-985.
[33] Ning S, Fuessel S, Kotzsch M,et al. siRNA-mediated down-regulation of surviving inhibits bladder cancer cell growth. Int J Oncol, 2004,25(4): 1065-1071.
[34] Yang SM, Wen DG, Hou JQ,et al. Establishment and application of an orthotopic murine bladder cancer model. Ai Zheng, 2007,26(4):341-345.
[35] Cho HJ, Kim JK, Kim KD,et al. Upregulation of Bcl-2 is associated with cisplatin- resistance via inhibition of Bax translocation in human bladder cancer cells.Cancer Lett, 2006 ,237(1):56-66.
[36] Tararova ND, Narizhneva N, Krivokrisenko V,et al. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate, 2007, 67(16): 1801-1815.
[37] Xu XF, Zhang ZY, Ge JP, et al. RNA interference-mediated silencing of the PAR gene inhibits the growth of PC3 cells via the induction of G2/M cell cycle arrest and apoptosis. J Gene Med, 2007,9(12): 1065-1070.
[38] Stettner M, Kaulfuss S, Burfeind P,et al. The relevance of estrogen receptor- {beta} expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther, 2007, 6(10): 2626-2633.
[39] Thelen P, Burfeind P, Schweyer S,et al. Molecular principles of alternative treatment approaches for hormone-refractory prostate cancer. Urologe A, 2007,46(9): 1271-1274.
[40] Sahadevan K, Darby S, Leung HY,et al. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol, 2007, 213(1): 82- 90.
[41] Zhang L, Gao L, Zhao L,et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res, 2007,67(12):5859-5864.
[42] El Touny LH, Banerjee PP. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun, 2007, 361(1):169-175.
[43] Spierings DC, de Vries EG, Stel AJ,et al. Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene, 2004, 23(28): 4862-4872.
[44] Lee JH, Schutte D, Wulf G,et al. Stem-cell protein Piwi12 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet, 2006,15(2): 201-211.
[45] Minakuchi Y, Takeshita F, Kosaka N,et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res, 2004,32(13):e109.